RespireRx Pharmaceuticals Inc (RSPI)

[senderos]

Here it is:


Glen Rock, N.J., September 8, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Rodman & Renshaw 18th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York, New York on Monday, September 12, 2016 at 4:15 PM ET. The Conference is sponsored by H.C. Wainwright & Co., LLC and is being held on September 12 and 13, 2016. Dr. Manuso will be available for one-on-one meetings with Conference attendees on both days.

Commented Dr. Manuso, “The presentation at the Rodman & Renshaw Conference will allow us to provide investors with an update on RespireRx’s recent reverse stock split, strategic initiatives and progress on research and development programs. In particular, I look forward to discussing preliminary, top-line results of the Company’s recently concluded Phase 2A clinical trial testing the impact of the Company’s proprietary oral ampakine, CX-1739, on opioid-induced respiratory depression.” Dr. Manuso also will discuss the Company’s other product pipeline candidates, including dronabinol, and the Company’s development timelines. Dr. Manuso concluded, “We are pleased to keep our shareholders and other stakeholders informed as to the continuing progress of RespireRx’s scientific, clinical and regulatory development initiatives.”

Dr. Manuso’s live presentation and accompanying slides will be accessible on Monday, September 12, 2016 at 4:15 PM ET using the following link: http://wsw.com/webcast/rrshq26/rspi. The presentation and slides will be accessible after the presentation by clicking on the investors tab on the RespireRx web-site at www.respirerx.com . A copy of the slide presentation being presented at the Conference will be submitted in a Form 8-K filing with the U.S. Securities and Exchange Commission prior to the presentation.

About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders, with a focus on drug-induced respiratory depression and sleep apneas. The Company holds exclusive licenses and owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.

RespireRx has a pipeline of medicines in Phase 2 clinical development focused on pharmaceutical treatments for a variety of different breathing disorders. Clinical development in the area of respiratory disorders, particularly drug-induced respiratory depression and sleep apnea, has created opportunities for the development and commercialization of the Company’s compounds.